- Home
- SBGI vs JANX Comparison
SBGI vs JANX Comparison
Compare SBGI & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBGI | JANX |
|---|---|---|
| Founded | 1986 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 975.7M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SBGI | JANX |
|---|---|---|
| Price | $13.55 | $19.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $22.00 | ★ $47.00 |
| AVG Volume (30 Days) | 366.3K | ★ 782.0K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,169,000,000.00 | $10,000,000.00 |
| Revenue This Year | $12.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.46 | $12.12 |
| 52 Week High | $17.88 | $35.34 |
Technical Indicators
Market Signals| Indicator | SBGI | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 62.63 |
| Support Level | $13.13 | $13.00 |
| Resistance Level | $14.48 | N/A |
| Average True Range (ATR) | 0.41 | 0.72 |
| MACD | -0.08 | 0.11 |
| Stochastic Oscillator | 13.04 | 67.63 |
Price Performance
Historical ComparisonAbout SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay TV distributors.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.